Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants

British Journal of Surgery

Volumn 92, Issue 6, 2005, Pages 681-687

  Wilson, C H ^a   Brook, N R ^b   Gok, M A ^a   Asher, J F ^a   Nicholson, M L ^b   Talbot, D ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ZENEPAX;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT REJECTION; HEART BEAT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; STATISTICS, NONPARAMETRIC; TACROLIMUS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 20844450709     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4976     Document Type: Conference Paper

References (30)

1. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart-beating donors. Transplant Proc 1995; 27: 2893-2894.
2. Feduska NJ Jr, Cecka JM. Donor factors. Clin Transpl 1994; 381-394.
3. Balupuri S, Buckley P, Snowden C, Mustafa M, Sen B, Griffiths P et al. The trouble with kidneys derived from the non heart-beating donor: a single center 10-year experience. Transplantation 2000; 69: 842-846.
4. Rosenthal JT, Danovitch GM, Wilkinson A, Ettenger RB. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991; 51: 1115-1118.
5. Almond PS, Troppmann C, Escobar F, Frey DJ, Matas AJ. Economic impact of delayed graft function. Transplant Proc 1991; 23: 1304.
6. Shoskes DA, Shahed AR, Kim S. Delayed graft function. Influence on outcome and strategies for prevention. Urol Clin North Am 2001; 28: 721-732.
7. Land W. Delayed graft function and renal allograft outcome. Transplantation 1999; 68: 452-453.
8. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967-2974.
9. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993; 17: 60-68.
10. Curtis JJ. Renovascular elements of the cyclosporine injury. Transplant Proc 1996; 28: 2094-2096.
11. Dunlop P, Varty K, Veitch PS, Nicholson ML, Bell PR. Non-heart-beating donors: the Leicester experience. Transplant Proc 1995; 27: 2940-2941; discussion 2935-2939.
12. Heineman E, Daemen JH, Kootstra G. Non-heart-beating donors: methods and techniques. Transplant Proc 1995; 27: 2896-2897.
13. Gok MA, Shenton BK, Buckley PE, Peaston R, Cornell C, Soomro N et al. How to improve the quality of kidneys from non-heart-beating donors: a randomised controlled trial of thrombolysis in non-heart-beating donors. Transplantation 2003; 76: 1714-1719.
14. Gok MA, Buckley PE, Shenton BK, Balupuri S, El-Sheikh MA, Robertson H et al. Long-term renal function in kidneys from non-heart-beating donors: a single-center experience. Transplantation 2002; 74: 664-669.
15. Solez K, Benediktsson H, Cavallo T, Croker B, Demetris AJ, Drachenberg C et al. Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996; 28: 441-444.
16. Benvenisty AI, Cohen D, Stegall MD, Hardy MA. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990; 49: 321-327.
17. Lange H, Muller TF, Ebel H, Kuhlmann U, Grebe SO, Heymanns J et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int 1999; 12: 2-9.
18. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128: 817-826.
19. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657-662.
20. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML et al. A prospective, randomized, clinical trial of intraoperative vs. postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798-802.
21. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
22. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789-792.
23. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-176.
24. Sanchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, Garcia Mena M et al. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors. Transplant Proc 2003; 35: 1689-1690.
25. Ciancio G, Burke GW, Suzart K, Mattiazzi A, Vaidya A, Roth D et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transplant 2003; 3: 1010-1016.
26. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 2001; 71: 1320-1328.
27. Tanabe K, Oshima T, Tokumoto T, Ishikawa N, Kanematsu A, Shinmura H et al. Long-term renal function in non-heart-beating donor kidney transplantation: a single-center experience. Transplantation 1998; 66: 1708-1713.
28. Schlumpf R, Weber M, Weinreich T, Spahn D, Rothlin M, Candinas D. Transplantation of kidneys from non-heart-beating donors: protocol, cardiac death diagnosis, and results. Transplant Proc 1996; 28: 107-109.
29. Hansen TN, D'Alessandro A, Southard JH. Reduced renal vascular injury following warm ischemia and preservation by hypothermic machine perfusion. Transplant Proc 1997; 29: 3577-3579.
30. National Institute for Clinical Excellence. Final Appraisal Determination: Immunosuppressive Therapy for Renal Transplantation. NICE: London, 2004.